A detailed history of Geode Capital Management, LLC transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,388,639 shares of MCRB stock, worth $819,297. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,388,639
Previous 1,133,625 22.5%
Holding current value
$819,297
Previous $816,000 61.64%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.7 - $1.48 $178,509 - $377,420
255,014 Added 22.5%
1,388,639 $1.32 Million
Q2 2024

Aug 09, 2024

SELL
$0.56 - $1.19 $559,450 - $1.19 Million
-999,018 Reduced 46.84%
1,133,625 $816,000
Q1 2024

May 13, 2024

BUY
$0.75 - $1.56 $28,953 - $60,222
38,604 Added 1.84%
2,132,643 $1.64 Million
Q4 2023

Feb 13, 2024

BUY
$0.93 - $2.15 $99,026 - $228,932
106,480 Added 5.36%
2,094,039 $2.93 Million
Q3 2023

Nov 13, 2023

BUY
$2.33 - $5.07 $61,048 - $132,839
26,201 Added 1.34%
1,987,559 $4.73 Million
Q2 2023

Aug 11, 2023

BUY
$4.67 - $6.55 $1.52 Million - $2.13 Million
325,849 Added 19.92%
1,961,358 $9.39 Million
Q1 2023

May 15, 2023

BUY
$4.95 - $6.09 $223,314 - $274,744
45,114 Added 2.84%
1,635,509 $9.27 Million
Q4 2022

Feb 13, 2023

BUY
$5.09 - $9.05 $427,056 - $759,304
83,901 Added 5.57%
1,590,395 $8.91 Million
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $1.01 Million - $2.07 Million
287,746 Added 23.61%
1,506,494 $9.67 Million
Q2 2022

Aug 12, 2022

BUY
$2.7 - $7.62 $25,463 - $71,864
9,431 Added 0.78%
1,218,748 $4.18 Million
Q1 2022

May 13, 2022

SELL
$6.3 - $8.84 $176,683 - $247,917
-28,045 Reduced 2.27%
1,209,317 $8.61 Million
Q4 2021

Feb 11, 2022

BUY
$6.02 - $11.43 $1.7 Million - $3.22 Million
282,018 Added 29.52%
1,237,362 $10.3 Million
Q3 2021

Nov 12, 2021

SELL
$5.46 - $22.6 $824,339 - $3.41 Million
-150,978 Reduced 13.65%
955,344 $6.65 Million
Q2 2021

Aug 13, 2021

BUY
$18.46 - $24.36 $2.46 Million - $3.25 Million
133,278 Added 13.7%
1,106,322 $26.4 Million
Q1 2021

May 12, 2021

BUY
$17.66 - $28.92 $1.54 Million - $2.52 Million
86,999 Added 9.82%
973,044 $20 Million
Q4 2020

Feb 12, 2021

BUY
$23.25 - $37.73 $2.02 Million - $3.28 Million
86,911 Added 10.88%
886,045 $21.7 Million
Q3 2020

Nov 13, 2020

BUY
$3.74 - $28.74 $228,188 - $1.75 Million
61,013 Added 8.27%
799,134 $22.6 Million
Q2 2020

Aug 13, 2020

BUY
$3.04 - $6.2 $232,265 - $473,698
76,403 Added 11.55%
738,121 $3.51 Million
Q1 2020

May 14, 2020

BUY
$2.64 - $3.82 $107,667 - $155,791
40,783 Added 6.57%
661,718 $2.36 Million
Q4 2019

Feb 13, 2020

BUY
$2.99 - $4.42 $218,488 - $322,982
73,073 Added 13.34%
620,935 $2.14 Million
Q3 2019

Nov 12, 2019

BUY
$2.29 - $4.16 $198,671 - $360,904
86,756 Added 18.81%
547,862 $2.2 Million
Q2 2019

Aug 14, 2019

BUY
$2.28 - $7.35 $417,579 - $1.35 Million
183,149 Added 65.89%
461,106 $1.48 Million
Q1 2019

May 14, 2019

BUY
$4.83 - $7.21 $194,083 - $289,719
40,183 Added 16.9%
277,957 $1.91 Million
Q4 2018

Feb 13, 2019

BUY
$4.52 - $8.88 $51,871 - $101,906
11,476 Added 5.07%
237,774 $1.07 Million
Q3 2018

Nov 13, 2018

SELL
$7.33 - $9.23 $725 - $913
-99 Reduced 0.04%
226,298 $1.72 Million
Q2 2018

Aug 14, 2018

SELL
$6.91 - $9.55 $7,773 - $10,743
-1,125 Reduced 0.49%
226,397 $1.95 Million
Q1 2018

May 15, 2018

BUY
$7.34 - $11.16 $133,052 - $202,297
18,127 Added 8.66%
227,522 $1.67 Million
Q4 2017

Feb 13, 2018

BUY
$9.15 - $12.64 $348,733 - $481,748
38,113 Added 22.25%
209,395 $2.12 Million
Q3 2017

Nov 14, 2017

BUY
$12.81 - $16.85 $15,205 - $20,000
1,187 Added 0.7%
171,282 $2.75 Million
Q2 2017

Aug 14, 2017

BUY
N/A
170,095
170,095 $1.92 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $73.2M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.